Skip to main content
Erschienen in: Die Pathologie 4/2023

01.06.2023 | Tumoren der Speicheldrüsen | Schwerpunkt: Kopf-Hals-Pathologie – neue WHO-Klassifikation

Neues zu Tumoren der Speicheldrüsen

WHO-Klassifikation 2022

verfasst von: Prof. Dr. Stephan Ihrler, Philipp Jurmeister, Christian Haas, Lukas Greber, Abbas Agaimy

Erschienen in: Die Pathologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der 5. Ausgabe der WHO-Klassifikation 2022 für Tumoren der Kopf-Hals-Region ist eine erneute leichte Zunahme bei benignen und malignen Tumorentitäten der Speicheldrüsen zu verzeichnen. Daneben gibt es sowohl konzeptionelle als auch rein terminologische Änderungen. Einige Festlegungen sind als vorläufig zu betrachten und einige weitere gelten als sehr umstritten (z. B. die Terminologie des intraduktalen Karzinoms). Die Bedeutung molekularpathologischer Befunde, insbesondere von rekurrenten Genfusionen, nimmt weiterhin stark zu und sie wurden teilweise in die Definition von Tumorentitäten aufgenommen. Ihre Bedeutung bleibt wie bisher weitgehend auf diagnostische Aspekte beschränkt. Zu den neu aufgenommenen Entitäten zählen das mikrosekretorische Karzinom (definiert durch eine SS18::MEF2C-Fusion), das sklerosierende mikrozystische Adenokarzinom (ähnelt den gleichnamigen Hautadnextumoren) und das muzinöse Adenokarzinom (charakterisiert durch AKT1-Mutationen bei heterogener Morphologie).
Literatur
1.
Zurück zum Zitat El-Naggar AK et al. (2017) WHO Classification of Head and Neck Tumours, 4. Aufl. International Agency for Research on Cancer, Lyon El-Naggar AK et al. (2017) WHO Classification of Head and Neck Tumours, 4. Aufl. International Agency for Research on Cancer, Lyon
2.
Zurück zum Zitat AUTHOR (2022) WHO Classification of Head and Neck Tumours, 5. Aufl. International Agency for Research on Cancer, Lyon AUTHOR (2022) WHO Classification of Head and Neck Tumours, 5. Aufl. International Agency for Research on Cancer, Lyon
3.
Zurück zum Zitat Skálová A et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):11–27CrossRef Skálová A et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):11–27CrossRef
4.
Zurück zum Zitat Haller F et al (2020) Nuclear NR4A2 (Nurr1) Immunostaining is a novel marker for acinic cell carcinoma of the salivary glands lacking the classic NR4A3 (NOR-1) upregulation. Am J Surg Pathol 44(9):1290–1292CrossRefPubMed Haller F et al (2020) Nuclear NR4A2 (Nurr1) Immunostaining is a novel marker for acinic cell carcinoma of the salivary glands lacking the classic NR4A3 (NOR-1) upregulation. Am J Surg Pathol 44(9):1290–1292CrossRefPubMed
5.
Zurück zum Zitat Bishop JA et al (2019) Microsecretory adenocarcinoma: a novel salivary gland tumor characterized by a recurrent MEF2C-SS18 fusion. Am J Surg Pathol 43(8):1023–1032CrossRefPubMed Bishop JA et al (2019) Microsecretory adenocarcinoma: a novel salivary gland tumor characterized by a recurrent MEF2C-SS18 fusion. Am J Surg Pathol 43(8):1023–1032CrossRefPubMed
6.
Zurück zum Zitat Bishop JA et al (2021) Microsecretory adenocarcinoma of salivary glands: an expanded series of 24 cases. Head Neck Pathol 15(4):1192–1201CrossRefPubMedPubMedCentral Bishop JA et al (2021) Microsecretory adenocarcinoma of salivary glands: an expanded series of 24 cases. Head Neck Pathol 15(4):1192–1201CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Jurmeister P et al (2022) New entity of microsecretory adenocarcinoma of salivary glands: first case with recurrence and metastases—proof of malignancy. Virchows Arch Jurmeister P et al (2022) New entity of microsecretory adenocarcinoma of salivary glands: first case with recurrence and metastases—proof of malignancy. Virchows Arch
8.
Zurück zum Zitat Skálová A, Hyrcza MD, Leivo I (2022) Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1):40–53CrossRefPubMedPubMedCentral Skálová A, Hyrcza MD, Leivo I (2022) Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1):40–53CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ihrler S et al (2021) Why is the histomorphological diagnosis of tumours of minor salivary glands much more difficult? Histopathology 79(5):779–790CrossRefPubMed Ihrler S et al (2021) Why is the histomorphological diagnosis of tumours of minor salivary glands much more difficult? Histopathology 79(5):779–790CrossRefPubMed
10.
Zurück zum Zitat Mills AM et al (2016) Sclerosing microcystic adenocarcinoma of the head and neck mucosa: a neoplasm closely resembling microcystic adnexal carcinoma. Head Neck Pathol 10(4):501–508CrossRefPubMedPubMedCentral Mills AM et al (2016) Sclerosing microcystic adenocarcinoma of the head and neck mucosa: a neoplasm closely resembling microcystic adnexal carcinoma. Head Neck Pathol 10(4):501–508CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Rooper LM et al (2021) Salivary mucinous adenocarcinoma is a Histologically diverse single entity with recurrent AKT1 E17K mutations: Clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol 45(10):1337–1347CrossRefPubMed Rooper LM et al (2021) Salivary mucinous adenocarcinoma is a Histologically diverse single entity with recurrent AKT1 E17K mutations: Clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol 45(10):1337–1347CrossRefPubMed
12.
Zurück zum Zitat Agaimy A et al (2018) Intraductal papillary mucinous neoplasms of minor salivary glands with AKT1 p.Glu17Lys mutation. Am J Surg Pathol 42(8):1076–1082CrossRefPubMed Agaimy A et al (2018) Intraductal papillary mucinous neoplasms of minor salivary glands with AKT1 p.Glu17Lys mutation. Am J Surg Pathol 42(8):1076–1082CrossRefPubMed
13.
Zurück zum Zitat Yang S, Zeng M, Chen X (2019) Intraductal papillary mucinous neoplasm of the minor salivary gland with associated invasive micropapillary carcinoma. Am J Surg Pathol 43(10):1439–1442CrossRefPubMed Yang S, Zeng M, Chen X (2019) Intraductal papillary mucinous neoplasm of the minor salivary gland with associated invasive micropapillary carcinoma. Am J Surg Pathol 43(10):1439–1442CrossRefPubMed
14.
Zurück zum Zitat Agaimy A (2021) Papillary neoplasms of the salivary duct system: a review. Surg Pathol Clin 14(1):53–65CrossRefPubMed Agaimy A (2021) Papillary neoplasms of the salivary duct system: a review. Surg Pathol Clin 14(1):53–65CrossRefPubMed
15.
Zurück zum Zitat McLean AC et al (2022) A subset of salivary intercalated duct lesions harbors recurrent CTNNB1 and HRAS mutations: a molecular link to basal cell adenoma and epithelial-myoepithelial carcinoma? Head Neck Pathol McLean AC et al (2022) A subset of salivary intercalated duct lesions harbors recurrent CTNNB1 and HRAS mutations: a molecular link to basal cell adenoma and epithelial-myoepithelial carcinoma? Head Neck Pathol
16.
Zurück zum Zitat Rooper LM et al (2022) Recurrent IDH2 mutations in salivary gland striated duct adenoma define an expanded histologic spectrum distinct from canalicular adenoma. Surg Pathol Clin Rooper LM et al (2022) Recurrent IDH2 mutations in salivary gland striated duct adenoma define an expanded histologic spectrum distinct from canalicular adenoma. Surg Pathol Clin
17.
Zurück zum Zitat Skálová A et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):e11–e27CrossRefPubMed Skálová A et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42(2):e11–e27CrossRefPubMed
18.
Zurück zum Zitat Skálová A et al (2020) Molecular profiling of salivary oncocytic mucoepidermoid carcinomas helps to resolve differential diagnostic dilemma with low-grade oncocytic lesions. Am J Surg Pathol 44(12):1612–1622CrossRefPubMed Skálová A et al (2020) Molecular profiling of salivary oncocytic mucoepidermoid carcinomas helps to resolve differential diagnostic dilemma with low-grade oncocytic lesions. Am J Surg Pathol 44(12):1612–1622CrossRefPubMed
19.
Zurück zum Zitat Agaimy A et al (2021) ALK rearrangements characterize 2 distinct types of salivary gland carcinomas: Clinicopathologic and molecular analysis of 4 cases and literature review. Am J Surg Pathol 45(9):1166–1178CrossRefPubMed Agaimy A et al (2021) ALK rearrangements characterize 2 distinct types of salivary gland carcinomas: Clinicopathologic and molecular analysis of 4 cases and literature review. Am J Surg Pathol 45(9):1166–1178CrossRefPubMed
20.
Zurück zum Zitat Rooper LM et al (2021) The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary Immunohistochemical profiling and diagnostic criteria. Am J Surg Pathol 45(6):753–764CrossRefPubMed Rooper LM et al (2021) The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary Immunohistochemical profiling and diagnostic criteria. Am J Surg Pathol 45(6):753–764CrossRefPubMed
21.
Zurück zum Zitat Bishop JA et al (2020) Sclerosing polycystic “adenosis” of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol 14(3):630–636CrossRefPubMed Bishop JA et al (2020) Sclerosing polycystic “adenosis” of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol 14(3):630–636CrossRefPubMed
22.
Zurück zum Zitat Xu B et al (2020) Histologic classification and molecular signature of polymorphous adenocarcinoma (PAC) and cribriform adenocarcinoma of salivary gland (CASG): an international Interobserver study. Am J Surg Pathol 44(4):545–552CrossRefPubMedPubMedCentral Xu B et al (2020) Histologic classification and molecular signature of polymorphous adenocarcinoma (PAC) and cribriform adenocarcinoma of salivary gland (CASG): an international Interobserver study. Am J Surg Pathol 44(4):545–552CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Barnes L et al (2005) WHO classification of tumours. Pathology and genetics, head and neck tumours. International Agency for Research on Cancer, Lyon Barnes L et al (2005) WHO classification of tumours. Pathology and genetics, head and neck tumours. International Agency for Research on Cancer, Lyon
24.
25.
Zurück zum Zitat Thompson LDR et al (2020) Don’t stop the champions of research now: a brief history of head and neck pathology developments. Hum Pathol 95:1–23CrossRefPubMed Thompson LDR et al (2020) Don’t stop the champions of research now: a brief history of head and neck pathology developments. Hum Pathol 95:1–23CrossRefPubMed
26.
Zurück zum Zitat Bishop JA (2013) Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head and Neck Pathol 7(1):35–39CrossRef Bishop JA (2013) Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head and Neck Pathol 7(1):35–39CrossRef
27.
Zurück zum Zitat Bishop JA et al (2021) The myoepithelial cells of salivary intercalated duct-type Intraductal carcinoma are neoplastic: a study using combined whole-slide imaging, immunofluorescence, and RET fluorescence in situ hybridization. Am J Surg Pathol 45(4):507–515CrossRefPubMed Bishop JA et al (2021) The myoepithelial cells of salivary intercalated duct-type Intraductal carcinoma are neoplastic: a study using combined whole-slide imaging, immunofluorescence, and RET fluorescence in situ hybridization. Am J Surg Pathol 45(4):507–515CrossRefPubMed
28.
Zurück zum Zitat Ihrler S et al (2022) Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements. Histopathology 82:576–586 Ihrler S et al (2022) Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements. Histopathology 82:576–586
29.
Zurück zum Zitat Ihrler S et al (2017) Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process. Virchows Arch 470(6):601–609CrossRefPubMed Ihrler S et al (2017) Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process. Virchows Arch 470(6):601–609CrossRefPubMed
30.
Zurück zum Zitat Agaimy A et al (2022) HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology. Am J Surg Pathol 46(2):190–199CrossRefPubMed Agaimy A et al (2022) HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology. Am J Surg Pathol 46(2):190–199CrossRefPubMed
Metadaten
Titel
Neues zu Tumoren der Speicheldrüsen
WHO-Klassifikation 2022
verfasst von
Prof. Dr. Stephan Ihrler
Philipp Jurmeister
Christian Haas
Lukas Greber
Abbas Agaimy
Publikationsdatum
01.06.2023
Verlag
Springer Medizin
Erschienen in
Die Pathologie / Ausgabe 4/2023
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-023-01194-5

Weitere Artikel der Ausgabe 4/2023

Die Pathologie 4/2023 Zur Ausgabe

Schwerpunkt: Kopf-Hals-Pathologie – neue WHO-Klassifikation

Spezielle mesenchymale Tumoren der Kopf-Hals-Region: Neues aus der WHO 2022

Schwerpunkt: Kopf-Hals-Pathologie – neue WHO-Klassifikation

Die neue WHO-Klassifikation der Kiefertumoren

Mitteilungen der Österreichischen Gesellschaft für Klinische Pathologie und Molekularpathologie

Mitteilungen der Österreichischen Gesellschaft für Klinische Pathologie und Molekularpathologie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.